BESTOW-EXTENSION: A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long- Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

You may be able to join if

• A participant meeting the following criteria at the time of baseline will be considered for admission to the study: Successfully completed qualifying Parent study, where entry into the OLE was offered;
• Continue to be able to understand the key components of the study as described in the written ICF, and is willing and able to provide written informed consent
• Agree not to participate in another interventional study while on treatment
• If female, is surgically sterile or 2 years postmenopausal. Women of childbearing potential may be enrolled if a pregnancy test is negative at baseline. Women of childbearing potential and men with partners that are of childbearing potential must agree to use highly effective methods of contraception from baseline through 120 days after the last administration of the study drug. Examples of acceptable methods of contraception are described in Table 6 and Table 7 (UK only)
• If male, agree to use a medically accepted highly effective method of contraception and agree to use this method for 120 days after last administration of the study drug and agree to not donate sperm for 120days after last administration of the study drug